Never before has any drug come out with the combination of effectiveness, popularity and cost as the new GLP-1 weight-loss drugs - Ozempic (for diabetes but used for weight loss), Wegovy and Mounjaro, with more on the way. That combination potentially makes coverage very expensive. On the other hand, employee benefits and coverage are a key differentiator in a tight labor market.
You’d like to understand the cost of coverage and how you can cover these without “breaking the bank.” This course shows you the one way to do that. And there is only one way, as it turns out.
Course Key Concepts: Weight-loss drugs, Ozempic, Wegovy, GLP-1, GLP-1s, semaglutides, Mounjaro, diabetes, obesity, prior authorization, drug benefit.
Learning Objectives
- Recognize the cost of unrestricted coverage with only the typical prior authorization.
- Identify the drivers of those costs within your organization.
- Explore creative ways to tamp down the cost of coverage.
- Discover the many side effects and potential complications that can discourage employee usage.
Prerequisites
No advanced preparation or prerequisites are required for this course.
Education Provider Information
![Instructor for this course Instructor for this course](https://www.illumeo.com/sites/proformative.com/files/imagecache/user_image_large/pictures/picture-70281-1461112640.jpg)